{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:53:29Z","timestamp":1791388409040,"version":"4.3.3"},"reference-count":26,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1136\/dtb.2025.000043","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:25Z","timestamp":1788451405000},"page":"130-132","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Can we do more to address long-term harms of medicine use? Learning from the DES (diethylstilboestrol) disaster"],"prefix":"10.1136","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-915X","authenticated-orcid":false,"given":"Barbara","family":"Mintzes","sequence":"first","affiliation":[{"name":"School of Pharmacy and Charles Perkins Centre, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Devine","sequence":"additional","affiliation":[{"name":"DES (diethylstilboestrol) Action NSW, Thornleigh, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026100708151170000_64.9.130.1","unstructured":"Toale J . Government acts to support generations of women impacted by pregnancy drug scandal within days of DES Justice Campaign launch. 2025. Available: https:\/\/www.jessicatoale.com\/post\/government-acts-to-support-generations-of-women-impacted-by-pregnancy-drug-scandal-within-days-of-de [Accessed 30 Apr 2026]."},{"key":"2026100708151170000_64.9.130.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197104222841604"},{"key":"2026100708151170000_64.9.130.3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ygyno.2017.06.028","article-title":"Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up","volume":"146","author":"Huo","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2026100708151170000_64.9.130.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013961"},{"key":"2026100708151170000_64.9.130.5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142575","article-title":"Benign and Malignant Outcomes in the Offspring of Females Exposed In Utero to Diethylstilbestrol (DES): An Update from the NCI Third Generation Study","volume":"16","author":"Titus","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026100708151170000_64.9.130.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2012.03.002"},{"key":"2026100708151170000_64.9.130.7","unstructured":"Mintzes B . Nous n\u2019avons pas eu de probl\u00e8me ici \u00bb l\u2019exp\u00e9rience internationale du des. [\u201cWe had no problems here.\u201d The international DES experience.]. In: Levadou A , Tournaire M , eds. DES (Distilb\u00e8ne - Stilboestrol) Trois g\u00e9n\u00e9rations: r\u00e9alit\u00e9s - perspectives [DES (diethylstilboestrol) three generations: realities - perspectives]. Mont de Marsan, France: R\u00e9seau DES France, 2010: 21\u201346."},{"key":"2026100708151170000_64.9.130.8","unstructured":"Corker S . Government admits state failed women given toxic pregnancy drug DES after ITV News investigation. ITV News; 2025. Available: https:\/\/www.itv.com\/news\/2025-09-10\/government-admits-state-failed-women-given-toxic-pregnancy-drug [Accessed 30 Apr 2026]."},{"key":"2026100708151170000_64.9.130.9","unstructured":"Wooldridge M. Minister for Health and Aged Care. Letter to Hon P. M. Ruddock, MP . Minister for Immigration and Cultural Affairs. Personal Communication. C Devine, DES Action NSW; 1999."},{"key":"2026100708151170000_64.9.130.10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0002-9378(48)90440-2","article-title":"Diethylstilbestrol in the prevention and treatment of complications of pregnancy","volume":"56","author":"Smith","year":"1948","journal-title":"Am J Obstet Gynecol"},{"key":"2026100708151170000_64.9.130.11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0002-9378(49)90204-5","article-title":"The influence of diethylstilbestrol on the progress and outcome of pregnancy as based on a comparison of treated with untreated primigravidas","volume":"58","author":"Smith","year":"1949","journal-title":"Am J Obstet Gynecol"},{"key":"2026100708151170000_64.9.130.12","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0002-9378(16)38617-3","article-title":"Does the administration of diethylstilbestrol during pregnancy have therapeutic value?","volume":"66","author":"Dieckmann","year":"1953","journal-title":"Am J Obstet Gynecol"},{"key":"2026100708151170000_64.9.130.13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0002-9378(83)90615-4","article-title":"Effect of stilbestrol on pregnancy compared to the effect of a placebo","volume":"65","author":"Ferguson","year":"1953","journal-title":"Am J Obstet Gynecol"},{"key":"2026100708151170000_64.9.130.14","first-page":"37","article-title":"Exposition au Distilb\u00e8ne\u00ae in utero: effets transg\u00e9n\u00e9rationnels [transgenerational effects of in utero DES exposure]","volume":"24","author":"Epelboin","year":"2022","journal-title":"M\u00e9decine de La Reproduction"},{"key":"2026100708151170000_64.9.130.15","unstructured":"Cody P . DES Voices. From Anger to Action (P11). San Francisco, USA; 2008. Available: www.lulu.com"},{"key":"2026100708151170000_64.9.130.16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1017\/S2040174420000872","article-title":"Prenatal diethylstilbestrol exposure and risk of diabetes, gallbladder disease, and pancreatic disorders and malignancies","volume":"12","author":"Troisi","year":"2021","journal-title":"J Dev Orig Health Dis"},{"key":"2026100708151170000_64.9.130.17","unstructured":"Simand S . DES Action Canada. personal communication. 2026."},{"key":"2026100708151170000_64.9.130.18","article-title":"Emerging Trends For Products Liability: Market Share Liability, Its History and Future","volume":"15","author":"Giliberti","year":"1999","journal-title":"Touro Law Rev"},{"key":"2026100708151170000_64.9.130.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60087-7"},{"key":"2026100708151170000_64.9.130.20","unstructured":"Toale J . Women\u2019s Health Strategy. UK Parliament. Hansard. Volume 783. 2026. Available: https:\/\/hansard.parliament.uk\/Commons\/2026-04-16\/debates\/21F892BE-1073-4B6B-9ECC-904D61693EE1\/details"},{"key":"2026100708151170000_64.9.130.21","unstructured":"Australian Government: Cancer Australia . Diethylstilboestrol (DES). Available: https:\/\/www.canceraustralia.gov.au\/cancer-types\/cervical-cancer\/what-are-risk-factors-cervical-cancer\/diethylstilboestrol-des [Accessed 30 Jul 2026]."},{"key":"2026100708151170000_64.9.130.22","unstructured":"White R . Assistant Minister for Health and Aged Care, the Hon Rebecca White MP. Letter to DES Action NSW; 2025."},{"key":"2026100708151170000_64.9.130.23","unstructured":"Devine C . DES Action NSW. Letter to Hon Rebecca White, Assistant Minister for Health and Aged Care re Diethylstilboestrol Exposure in Australia, documenting data on reported cancer cases from the Australian Institute of Health and Welfare (n=266) and Therapeutic Goods Administration (n=20). 2026."},{"key":"2026100708151170000_64.9.130.24","unstructured":"Patterson K . Minister for Family and Community Services and Minister Assisting the Prime Minister for Women\u2019s Health Issues. Parliamentary Debates Senate Questions on Notice Diethylstilbestrol Hansard; 2005. Available: https:\/\/parlinfo.aph.gov.au\/parlInfo\/genpdf\/chamber\/hansards\/2005-08-17\/0160\/hansard_frag.pdf;fileType=application%2Fpdf [Accessed 10 May 2026]."},{"key":"2026100708151170000_64.9.130.25","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-021-00375-y","article-title":"A comparison of the Food and Drug Administration\u2019s and Health Canada\u2019s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study","volume":"14","author":"Lexchin","year":"2021","journal-title":"J Pharm Policy Pract"},{"key":"2026100708151170000_64.9.130.26","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-025-01082-1","article-title":"Application of Real-World Evidence to Support FDA Regulatory Decision Making","volume":"27","author":"Khaowroongrueng","year":"2025","journal-title":"AAPS J"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2025.000043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:15:18Z","timestamp":1791386118000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2025.000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/dtb.2025.000043"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2025.000043","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}